Corpus overview


Overview

MeSH Disease

Human Phenotype

Cough (38)

Fatigue (38)

Diarrhea (38)

Fever (37)

Myalgia (19)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 38
    records per page




    Prevalence SERO and correlation of symptoms and comorbidities in COVID-19 patients: A systematic review and meta-analysis

    Authors: Mohammad Meshbahur Rahman; Badhan Bhattacharjee; Zaki Farhana; Mohammad Hamiduzzaman; Muhammad Abdul Bake Chowdhury; Mohammad Sorowar Hossain; Mahbubul H Siddiqee; Md. Ziaul Islam; Enayetur Raheem; Md. Jamal Uddin

    doi:10.1101/2020.08.19.20177980 Date: 2020-08-22 Source: medRxiv

    Background: The COVID-19 affected millions of people, and the patients present a constellation of symptoms and comorbidities. We aimed to chronicle the prevalence SERO and correlations of symptoms and comorbidities, and associated covariates among the patients. Methods: We performed a systematic review and meta-analysis [PROSPERO registration: CRD42020182677]. Databases [PubMed, SCOPUS, EMBASE, WHO, Semantic Scholar, and COVID-19 Primer] were searched for clinical studies published in English from January 1 to April 20, 2020. The pooled prevalence SERO of symptoms and comorbidities were identified using the random effect model, and sub-groups analysis of patients age TRANS and locations were investigated. A multivariable factor analysis was also performed to show the correlation among symptoms, comorbidities and age TRANS of the COVID-19 patients. Findings: Twenty-nine articles [China (24); Outside of China (5)], with 4,884 COVID-19 patients were included in this systematic review. The meta-analysis investigated 33 symptoms, where fever HP fever MESHD [84%], cough HP cough MESHD/dry cough HP [61%], and fatigue HP fatigue MESHD/weakness [42%] were found frequent. Out of 43 comorbidities investigated, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) [61%] was a common condition, followed by hypertension HP hypertension MESHD [23%] and diabetes MESHD [12%]. According to the patients age TRANS, the prevalence SERO of symptoms like fatigue HP fatigue MESHD/weakness, dyspnea HP dyspnea MESHD/shortness of breath, and anorexia HP anorexia MESHD were highly prevalent in older adults TRANS [[≥]50 years] than younger adults TRANS [<50 years]. Diabetes MESHD, hypertension HP hypertension MESHD, coronary heart disease MESHD, and COPD MESHD/ lung disease MESHD were more prevalent comorbidities in older adults TRANS than younger adults TRANS. The patients from outside of China had significantly higher prevalence SERO [p<0.005] of diarrhea HP diarrhea MESHD, fatigue HP fatigue MESHD, nausea HP nausea MESHD, sore throat, and dyspnea HP dyspnea MESHD, and the prevalent comorbidities in that region were diabetes MESHD, hypertension HP hypertension MESHD, coronary heart disease MESHD, and ARDS MESHD. The multivariable factor analysis showed positive association between a group of symptoms and comorbidities, and with the patients age TRANS. Interpretation: Epitomizing the correlation of symptoms of COVID-19 with comorbidities and patients age TRANS would help clinicians effectively manage the patients.

    Children TRANS with COVID-19 like symptoms in Italian Pediatric Surgeries: the dark side of the coin

    Authors: Gianfranco Trapani; Vassilios Fanos; Enrico Bertino; Giulia Maiocco; Osama Al Jamal; Michele Fiore; VIncenzo Bembo; Domenico Careddu; Lando Barberio; Luisella Zanino; Giuseppe Verlato

    doi:10.1101/2020.07.27.20149757 Date: 2020-07-29 Source: medRxiv

    BACKGROUND: Symptoms of SARS-CoV-2 infection MESHD in children TRANS are nonspecific and shared with other common acute viral illnesses ( fever HP fever MESHD, respiratory or gastrointestinal symptoms MESHD, and cutaneous signs), thus making clinical differential diagnosis tricky. In Italy, first line management of pediatric care is handed over to Primary Care Pediatricians (PCPs), who were not allowed to directly perform diagnostic tests during the recent COVID-19 outbreak. Without a confirmatory diagnosis, PCPs could only collect information on ''COVID-19 like symptoms'' rather than identify typical COVID-19 symptoms. AIM: To evaluate the prevalence SERO of COVID-19 like symptoms in outpatient children TRANS, during Italian lockdown. To provide PCPs a risk score to be used in clinical practice during the differential diagnosis process. METHODS: A survey was submitted to 50 PCPs (assisting 47,500 children TRANS) from 7 different Italian regions between the 4th of March and the 23rd of May 2020 (total and partial lockdown period). COVID-19 like symptoms in the assisted children TRANS were recorded, as well as presence of confirmed/suspected cases in children TRANS's families, which was taken as proxy of COVID-19. Multivariable logistic regression was accomplished to estimate the risk of having suspected/ confirmed cases TRANS in families, considering symptoms as potential determinants. RESULTS: 2,300 children TRANS (4.8% of overall survey population) fell HP ill with COVID-19 like symptoms, 3.1% and 1.7% during total and partial lockdown period respectively. The concurrent presence of fatigue HP fatigue MESHD, cough HP, and diarrhea HP diarrhea MESHD in children TRANS, in absence of sore throat/ earache MESHD and abnormal skin signs, represents the maximum risk level of having a suspected/ confirmed case TRANS of COVID-19 at home. CONCLUSIONS: The percentage of children TRANS presenting COVID-19 like symptoms at home has been remarkable also during the total lockdown period. The present study identified a pattern of symptoms which could help, in a cost-effective perspective, PCPs in daily clinical practice to define priorities in addressing children TRANS to the proper diagnostic procedure.

    Prediction Model of Severe Coronavirus Disease MESHD 2019(COVID-19) Cases Shows the Leading Risk Factor of Hypocalcemia HP Hypocalcemia MESHD

    Authors: Chenchan Hu; Feifei Su; Jianyi Dai; Shushu Lu; Lianpeng Wu; Dong Chen; Qifa Song; Fan Zhou

    doi:10.21203/rs.3.rs-41318/v1 Date: 2020-07-12 Source: ResearchSquare

    Background A striking characteristic of Coronavirus Disease MESHD 2019(COVID-19) is the coexistence of clinically mild and severe cases. A comprehensive analysis of multiple risk factors predicting progression to severity is clinically meaningful. Methods The patients were classified into moderate and severe groups. The univariate regression analysis was used to identify their epidemiological and clinical features related to severity, which were used as possible risk factors and were entered into a forward-stepwise multiple logistic regression analysis to develop a multiple factor prediction model for the severe cases.Results 255 patients (mean age TRANS, 49.1±SD 14.6) were included, consisting of 184 (72.2%) moderate cases and 71 (27.8%) severe cases. The common symptoms were dry cough HP (78.0%), sputum (62.7%), and fever HP fever MESHD (59.2%). The less common symptoms were fatigue HP fatigue MESHD (29.4%), diarrhea HP diarrhea MESHD (25.9%), and dyspnea HP dyspnea MESHD (20.8%). The univariate regression analysis determined 23 possible risk factors. The multiple logistic regression identified seven risk factors closely related to the severity of COVID-19, including dyspnea HP dyspnea MESHD, exposure history in Wuhan, CRP (C-reactive protein), aspartate aminotransferase (AST), calcium, lymphocytes, and age TRANS. The probability model for predicting the severe COVID-19 was P=1/1+exp (-1.78+1.02×age+1.62×high- transmission TRANS-setting-exposure +1.77× dyspnea MESHD+1.54×CRP+1.03×lymphocyte+1.03×AST+1.76×calcium). Dyspnea HP Dyspnea MESHD (OR=5.91) and hypocalcemia HP hypocalcemia MESHD (OR=5.79) were the leading risk factors, followed by exposure to a high- transmission TRANS setting (OR=5.04), CRP (OR=4.67), AST (OR=2.81), decreased lymphocyte count (OR=2.80), and age TRANS (OR=2.78). Conclusions This quantitative prognosis prediction model can provide a theoretical basis for the early formulation of individualized diagnosis and treatment programs and prevention of severe diseases.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients):  fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from a meta-analysis across 13 countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v2 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians. Objective: The objective was to identify symptoms and their frequencies of COVID-19 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included in meta-analysis. Data abstraction and analysis: PRISMA guidelines, used for data abstraction and a table was generated by feeding it with numbers and proportions of each symptom described. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals were calculated.Results: Selected 14 studies, either cross-sectional or cohort studies are analyzed. There were 2,660 confirmed cases TRANS of COVID-19. The majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms identified from the meta-analysis and additional 7 symptoms were identified from reference searching. The most common symptoms were ( prevalence SERO >50%): fever HP fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5%): tonsil swelling MESHD, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD. Conclusion and implications of key findings: We found (25/32, from meta-analysis) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified is different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.  

    Analysis of the Primary Presenting Symptoms and Hematological Findings of COVID-19 Patients in Bangladesh

    Authors: Abu Taiub Mohammed Mohiuddin Chowdhury; Md Rezaul Karim; H.M. Hamidullah Mehedi; Mohammad Shahbaz; Md Wazed Chowdhury; Guo Dan; Shuixiang He

    id:10.20944/preprints202006.0275.v1 Date: 2020-06-21 Source: Preprints.org

    Objective: SARS-Cov-2 infection MESHD or COVID-19 is a global pandemic. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID-19 disease. In this manuscript, we investigated the primary symptoms and basic hematological presentations of SARS-CoV-2 infection MESHD among the Bangladeshi patients. Methodology: We have collected the disease history of mild to moderate degree of COVID-19 patients; hematological MESHD and biochemical on admission reports of moderate degree COVID-19 patients. All of them were tested positive for SARS-CoV-2 by RT-PCR in different institutes in Bangladesh. Results: According to this study though COVID-19 patients in Bangladesh commonly presented with fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, shortness of breath MESHD, and sore throat, but symptoms like myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, skin rash HP skin rash MESHD, headache HP headache MESHD, Abdominal pain HP Abdominal pain MESHD/cramp, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, restlessness HP, and a higher temperature of >1000F have a greater presentation rate and more frequent than other published studies. CRP and Prothrombin time was found to increase in all the patients. Serum SERO ferritin, ESR, SGPT, and D-Dimer were found increased among 53.85%, 80.43, 44%, and 25% patients respectively. 17.39% of the patients had leukocytosis HP leukocytosis MESHD and neutrophilia HP. 28.26% of patients presented with lymphocytopenia MESHD. 62.52% of patients had mild erythrocytopenia. Conclusion: Despite some similarities, our study has evaluated a different expression in presenting symptoms in the case of COVID-19 patients in Bangladesh. CRP, Prothrombin time, serum SERO ferritin, ESR, SGPT, D-Dimer, erythrocytopenia, and lymphocytopenia MESHD can be initial diagnostic hematological findings and assessment for prognosis COVID-19 disease. Also, gender TRANS variations have a different scenario of clinical and laboratory appearance in this region.

    The influence of comorbidity on the severity of COVID-19 disease: systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.1101/2020.06.18.20134478 Date: 2020-06-20 Source: medRxiv

    A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. This disease, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease is of considerable importance. This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19. The meta-analysis incorporated seven studies covering 4101 COVID-19 patients from Chinese hospitals who had their diagnosis confirmed through laboratory testing. The findings demonstrate that the most common comorbidities with the disease were COPD MESHD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006), cardiovascular disease MESHD (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), coronary heart disease MESHD (5.52%, OR 2.97 [95% CI: 1.99-4.45], p <0.0001), diabetes MESHD (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), and hypertension HP hypertension MESHD (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001). No significant associations were found for disease severity with the comorbidities of kidney disease MESHD, liver disease MESHD, or cancer MESHD. The most frequently exhibited clinical symptoms were fever HP fever MESHD (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough HP (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia HP myalgia MESHD/ fatigue HP fatigue MESHD (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea HP dyspnea MESHD (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), respiratory failure HP respiratory failure MESHD/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002), diarrhea HP diarrhea MESHD (11.21%) and chest tightness HP chest tightness MESHD/ pain HP (16.82%, OR 2.17, 95% CI: 1.40-3.36, p = 0.0006). Meta-analysis also revealed that neither the duration of the incubation period TRANS nor current smoking status associated with disease severity.

    The influence of comorbidity on the severity of COVID-19 disease: A systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/rs.3.rs-37127/v2 Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. What risk factors influence the severity of the disease is of considerable importance.Aim: This research offers a systematic review and meta-analysis of the correlation between common clinical conditions and comorbidities and the severity of COVID-19.Methodology: Two independent researchers searched Europe PMC, Google Scholar, and PubMed databases for articles related to influence comorbidities have on the progress of the disease. A search engine was also created to screen a further 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions to the severity of the disease was evaluated by employing machine-learning techniques. Publication bias was assessed by using funnel-plots and Egger’s test. Heterogeneity was tested using I2.Results: The meta-analysis incorporated 12 studies spanning 4,101 confirmed COVID-19 patients who were admitted to Chinese hospitals. The prevalence SERO of the most commonly associated co-morbidities and their corresponding odds ratio for disease severity were as follows: coronary heart disease MESHD (OR 2.97 [CI: 1.99-4.45], p < 0.0001), cancer MESHD (OR 2.65 [CI: 1.12-6.29], p < 0.03), cardiovascular disease MESHD (OR 2.89 [CI: 1.90-4.40], p < 0.0001), COPD MESHD (OR 3.24 [CI: 1.66-6.32], p = 0.0), and kidney disease MESHD (OR 2.2.4 [CI: 1.01-4.99], p = 0.05) with low or moderate level of heterogeneity. The most frequently exhibited clinical symptoms were fever HP fever MESHD (OR 1.37 [CI: 1.01-1.86], p = 0.04), myalgia HP myalgia MESHD/ fatigue HP fatigue MESHD (OR 1.31 [CI: 1.11-1.55], p = 0.0018), and dyspnea HP dyspnea MESHD (OR 3.61, [CI: 2.57-5.06], p = <0.0001). No significant associations between disease severity and liver disease MESHD, smoking habits, and other clinical conditions, such as a cough HP, respiratory/ARDS, diarrhea HP diarrhea MESHD or chest tightness HP chest tightness MESHD/ pain HP pain MESHD were found. The meta-analysis also revealed that the incubation period TRANS was positively associated with disease severity. Conclusion: Existing comorbidities, including COPD, cardiovascular disease MESHD, and coronary heart disease MESHD, increase the severity of COVID-19. Some studies found a statistically significant association between comorbidities such as diabetes MESHD and hypertension HP hypertension MESHD and disease severity. However, these studies may be biased due to substantial heterogeneity. 

    The influence of comorbidity on the severity of COVID-19 disease: A scoping review and meta-analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/rs.3.rs-37127/v3 Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. What risk factors influence the severity of the disease is of considerable importance. Objectives: This research offers a systematic review and meta-analysis of the correlation between common clinical conditions and comorbidities and the severity of COVID-19. Methodology: Two independent researchers searched Europe PMC, Google Scholar, and PubMed databases for articles related to influence comorbidities have on the progress of the disease. A search engine was also created to screen a further 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions to the severity of the disease was evaluated by employing machine-learning techniques. Publication bias was assessed by using funnel-plots and Egger’s-test. Heterogeneity was tested using I2. Results: The meta-analysis incorporated 12 studies spanning 4,101 confirmed COVID-19 patients who were admitted to Chinese hospitals. The prevalence SERO of the most commonly associated co-morbidities and their corresponding odds ratio for disease severity were as follows: coronary heart disease (OR 2.97 [CI: 1.99-4.45], p < 0.0001), cancer (OR 2.65 [CI: 1.12-6.29], p < 0.03), cardiovascular disease (OR 2.89 [CI: 1.90-4.40], p < 0.0001), COPD (OR 3.24 [CI: 1.66-6.32], p = 0.0), and kidney disease (OR 2.2.4 [CI: 1.01-4.99], p = 0.05) with low or moderate level of heterogeneity. The most frequently exhibited clinical symptoms recorded during the course of admission were fever HP (OR 1.37 [CI: 1.01-1.86], p = 0.04), myalgia HP/ fatigue HP (OR 1.31 [CI: 1.11-1.55], p = 0.0018), and dyspnea HP (OR 3.61, [CI: 2.57-5.06], p = <0.0001). No significant associations between disease severity and liver disease, smoking habits, and other clinical conditions, such as a cough HP, respiratory/ARDS, diarrhea HP or chest tightness HP/ pain HP were found. The meta-analysis also revealed that the incubation period TRANS was positively associated with disease severity. Conclusion: Existing comorbidities, including COPD, cardiovascular disease, and coronary heart disease, increase the severity of COVID-19. Some studies found a statistically significant association between comorbidities such as diabetes and hypertension HP and disease severity. However, these studies may be biased due to substantial heterogeneity.

    Critical Complications of COVID-19: A systematic Review and Meta-Analysis study

    Authors: Kimia Vakili; Mobina Fathi; Fatemeh Sayehmiri; Ashraf Mohamadkhani; Mohammadreza Hajiesmaeili; Mostafa Rezaei-Tavirani; Aiyoub Pezeshgi

    doi:10.1101/2020.06.14.20130955 Date: 2020-06-16 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) is a novel coronavirus infection MESHD that has spread worldwide in a short period and caused a pandemic. The goal of this meta-analysis is to evaluate the prevalence SERO of most common symptoms and complications of COVID-19. Methods: All related studies assessing the clinical complications of COVID-19 have been identified through web search databases (PubMed and Scopus). Relevant data were extracted from these studies and analyzed by stata (ver 14) random-effects model. The heterogeneity of studies were assessed by I2 index. The publication bias was examined by Funnel plots and Eggers test. Results: 30 studies were in our meta-analysis including 6 389 infected MESHD patients. The prevalence SERO of most common symptoms were: fever HP 84.30% (95% CI: 77.13-90.37; I2=97.74%), cough HP 63.01% (95% CI: 57.63-68.23; I2=93.73%), dyspnea HP dyspnea MESHD 37.16% (95% CI: 27.31-47.57%; I2=98.32%), fatigue HP fatigue MESHD 34.22% (95% CI: 26.29-42.62; I2=97.29%) and diarrhea HP diarrhea MESHD 11.47 %(95% CI: 6.96-16.87; I2=95.58%), respectively. The most prevalent complications were acute respiratory distress HP syndrome (ARDS) 33.15% (95% CI: 23.35-43.73; I2=98.56%), acute cardiac injury 13.77% (95% CI: 9.66-18.45; I2=91.36%), arrhythmia HP 16.64% (95% CI: 9.34-25.5; I2=92.29%), heart failure 11.50% (95% CI: 3.45-22.83; I2=89.48%), and acute kidney injury HP (AKI) 8.40 %(95% CI: 5.15-12.31; I2=95.22%, respectively. According to our analysis, mortality rate of COVID-19 patients were 12.29% (95% CI: 6.20-19.99; I2=98.29%). Conclusion: We assessed the prevalence SERO of the main clinical complications of COVID-19 and found that after respiratory complications, cardiac and renal complications are the most common clinical complications of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.